AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19000203 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from an other-gender peer
Number of subjects: 58
Study 19000203 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from a gender-unidentified peer
Number of subjects: 58
Study 19000203 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive feedback after initial failure
Number of subjects: 58
Study 15094031 — intervention group
Group type: EXPERIMENTAL
Intervention: standard treatment + soma
Number of subjects: 191
Study 15094031 — intervention group
Group type: EXPERIMENTAL
Intervention: standard treatment + relaxation training
Number of subjects: 191
Study 15094031 — intervention group
Group type: COMPARATOR
Intervention: waiting control group
Number of subjects: 191
Study 11765290 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall (ADL)
Number of subjects: 177
Study 11765290 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 177
Study 11765290 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 5 mg, 10 mg, 15 mg (various doses)
Number of subjects: 177
Study 9290370 — intervention group
Group type: EXPERIMENTAL
Intervention: DACE group (drainage, air injection, cryotherapy, and explant)
Number of subjects: 80
Study 9290370 — intervention group
Group type: EXPERIMENTAL
Intervention: CDAE group (cryotherapy, drainage, air injection, and explant)
Number of subjects: 80
Study 8115115 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized pachymetry (DGH 1000) measurements by three randomized operators
Number of subjects: 0
Study 8115115 — intervention group
Group type: EXPERIMENTAL
Intervention: Different patient positions (orthostatic and clinostatic)
Number of subjects: 0
Study 8115115 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal marking before and after measurements
Number of subjects: 0
Study 3521524 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin hydrochloride (mean maximal dose: 105 mg)
Number of subjects: 12
Study 3521524 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mean maximal dose: 128 mg)
Number of subjects: 12
Study 3521524 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin hydrochloride
Number of subjects: 12
Study 3521524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30955907 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulation
Number of subjects: 67
Study 30955907 — intervention group
Group type: COMPARATOR
Intervention: Sham (light touch approach)
Number of subjects: 67
Study 30955907 — intervention group
Group type: COMPARATOR
Intervention: Control (simple observation)
Number of subjects: 67
Study 28566124 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical melatonin 12.5%
Number of subjects: 0
Study 28566124 — intervention group
Group type: COMPARATOR
Intervention: Topical melatonin 0.5% and 2.5%
Number of subjects: 0
Study 28566124 — intervention group
Group type: COMPARATOR
Intervention: Placebo and no treatment
Number of subjects: 0
Study 26230471 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 5 mmol/L magnesium sulfate (MgSO4) solution for 14 days
Number of subjects: 73
Study 26230471 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control group)
Number of subjects: 73
Study 23733674 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab combined with docetaxel‐cisplatin‐fluorouracil regimen
Number of subjects: 9
Study 22357799 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal setting intervention (Exp, n = 16)
Number of subjects: 48
Study 22357799 — intervention group
Group type: COMPARATOR
Intervention: Therapist-led exercise therapy group (C1, n = 16)
Number of subjects: 48
Study 22357799 — intervention group
Group type: COMPARATOR
Intervention: Non-therapist-led exercise therapy group (C2, n = 16)
Number of subjects: 48
Study 19502459 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 42
Study 19502459 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 42
Study 17720117 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.26% wt/vol)
Number of subjects: 0
Study 17720117 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.30% wt/vol)
Number of subjects: 0
Study 17720117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.34% wt/vol)
Number of subjects: 0
Study 15323598 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort extract
Number of subjects: 112
Study 15323598 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant treatment
Number of subjects: 112
Study 10895973 — intervention group
Group type: EXPERIMENTAL
Intervention: FES-biofeedback
Number of subjects: 60
Study 10895973 — intervention group
Group type: COMPARATOR
Intervention: Intensive pelvic floor muscle exercise
Number of subjects: 60
Study 9495978 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin taken preventively before adverse reactions of alpha-IFN
Number of subjects: 0
Study 9495978 — intervention group
Group type: COMPARATOR
Intervention: Traditional routines of aspirin administration
Number of subjects: 0
Study 8374284 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic blood transfusion
Number of subjects: 0
Study 8374284 — intervention group
Group type: COMPARATOR
Intervention: Autologous blood transfusion
Number of subjects: 0
Study 3751672 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 69
Study 3751672 — intervention group
Group type: COMPARATOR
Intervention: metrizoate
Number of subjects: 69
Study 29641669 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet group (intervention)
Number of subjects: 702
Study 28477289 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.2–1.8 mg/kg/day) for 1 year, followed by randomization to atomoxetine for 6 months (n=81)
Number of subjects: 687
Study 28477289 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (80–100 mg/day) for 6 months, followed by randomization to atomoxetine for 6 months (n=266)
Number of subjects: 687
Study 28477289 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=82 in Study 1; n=258 in Study 2)
Number of subjects: 687
Study 28477289 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 687
Study 24807650 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned rural insurance benefit package
Number of subjects: 0
Study 24807650 — intervention group
Group type: COMPARATOR
Intervention: Combination of insurance intervention and capitation budget with pay-for-performance
Number of subjects: 0
Study 23910745 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence intervention (8 sessions)
Number of subjects: 0
Study 21719058 — intervention group
Group type: EXPERIMENTAL
Intervention: First academic quarter surgical patients
Number of subjects: 89473
Study 21719058 — intervention group
Group type: COMPARATOR
Intervention: Control group surgical patients
Number of subjects: 89473
Study 21719058 — intervention group
Group type: EXPERIMENTAL
Intervention: First academic quarter surgical patients undergoing artery bypass graft
Number of subjects: 89473
Study 21719058 — intervention group
Group type: COMPARATOR
Intervention: Control group surgical patients undergoing artery bypass graft
Number of subjects: 89473
Study 21719058 — intervention group
Group type: EXPERIMENTAL
Intervention: First academic quarter surgical patients undergoing repair bowel opening
Number of subjects: 89473
Study 21719058 — intervention group
Group type: COMPARATOR
Intervention: Control group surgical patients undergoing repair bowel opening
Number of subjects: 89473
Study 18339054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Sugar Low Yeast (LSLY) dietary intervention
Number of subjects: 52
Study 18339054 — intervention group
Group type: COMPARATOR
Intervention: Healthy Eating (HE) dietary intervention
Number of subjects: 52
Study 16551154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral group therapy
Number of subjects: 117
Study 16551154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral bibliotherapy
Number of subjects: 117
Study 16551154 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 117
Study 12663564 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 56
Study 12663564 — intervention group
Group type: COMPARATOR
Intervention: In-person
Number of subjects: 56
Study 12663564 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Telemedicine and In-person)
Number of subjects: 56
Study 11109693 — intervention group
Group type: EXPERIMENTAL
Intervention: Home safety assessment
Number of subjects: 252
Study 11109693 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 252
Study 9193431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ser447-Stop allele carriers (heterozygotes and homozygotes)
Number of subjects: 820
Study 9193431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ser447-Stop allele carriers using beta-blockers
Number of subjects: 820
Study 9193431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ser447-Stop allele carriers not using beta-blockers
Number of subjects: 820
Study 1604251 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (1000 mg)
Number of subjects: 17
Study 1604251 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methylprednisolone (375 mg)
Number of subjects: 17
Study 31830078 — intervention group
Group type: COMPARATOR
Intervention: Mass media campaign alone (Control)
Number of subjects: 2430
Study 31830078 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC attendance
Number of subjects: 2430
Study 31830078 — intervention group
Group type: EXPERIMENTAL
Intervention: General knowledge and awareness in the community (combined intervention)
Number of subjects: 2430
Study 28161789 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic extract (Creon®) 50,000 units with meals and 25,000 units with snacks
Number of subjects: 18
Study 28161789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28161789 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic extract (Creon®)
Number of subjects: 18
Study 26548851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cusum
Number of subjects: 48
Study 26548851 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 25107319 — intervention group
Group type: EXPERIMENTAL
Intervention: High trait anxious individuals
Number of subjects: 2
Study 25107319 — intervention group
Group type: COMPARATOR
Intervention: Low trait anxious individuals
Number of subjects: 2
Study 23101257 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antihypertensive therapy (long-acting verapamil combined with slow-release indapamide)
Number of subjects: 24
Study 23101257 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antihypertensive therapy (long-acting verapamil combined with enalapril)
Number of subjects: 24
Study 23101257 — intervention group
Group type: COMPARATOR
Intervention: Control group (verapamil plus indapamide)
Number of subjects: 24
Study 19446147 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose prednisone regimen (1 mg/kg daily)
Number of subjects: 41
Study 19446147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) combined with lower prednisone dose (0.5 mg/kg daily)
Number of subjects: 41
Study 18631345 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001
Number of subjects: 105
Study 18631345 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019
Number of subjects: 105
Study 18631345 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic groups (Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019)
Number of subjects: 105
Study 18631345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 16447665 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion
Number of subjects: 80
Study 16447665 — intervention group
Group type: COMPARATOR
Intervention: TCM and western drugs (Control)
Number of subjects: 80
Study 11822926 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic hydration (0.9% saline)
Number of subjects: 1620
Study 11822926 — intervention group
Group type: COMPARATOR
Intervention: Half-isotonic hydration (0.45% sodium chloride plus 5% glucose)
Number of subjects: 1620
Study 11822926 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic hydration
Number of subjects: 1620
Study 11822926 — intervention group
Group type: COMPARATOR
Intervention: Half-isotonic hydration
Number of subjects: 1620
Study 10413725 — intervention group
Group type: EXPERIMENTAL
Intervention: High ambient relative humidity (HRH) (85% relative humidity)
Number of subjects: 12
Study 10413725 — intervention group
Group type: COMPARATOR
Intervention: Low ambient relative humidity (LRH) (16% relative humidity)
Number of subjects: 12
Study 10413725 — intervention group
Group type: EXPERIMENTAL
Intervention: High ambient relative humidity (HRH)
Number of subjects: 12
Study 10413725 — intervention group
Group type: COMPARATOR
Intervention: Low ambient relative humidity (LRH)
Number of subjects: 12
Study 7720462 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesilate
Number of subjects: 5
Study 2127016 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) as add-on therapy
Number of subjects: 23
Study 6945060 — intervention group
Group type: COMPARATOR
Intervention: Vincristine (VCR) 2 mg/m2 on day 1 and Cyclophosphamide (CP) 450 mg/m2 on days 2 and 3 (two-drug regimen)
Number of subjects: 38
Study 6945060 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine (VCR) 2 mg/m2 on day 1, Cyclophosphamide (CP) 450 mg/m2 on days 2 and 3, and BCNU 50 mg on days 2 and 3 (three-drug regimen)
Number of subjects: 38
Study 31580695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Compression (IC)
Number of subjects: 24
Study 31580695 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Cupping
Number of subjects: 24
Study 31580695 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Therapy (IC + Dry Cupping)
Number of subjects: 24
Study 31103401 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive advice during PCI procedure
Number of subjects: 66
Study 31103401 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual advice on quitting smoking)
Number of subjects: 66
Study 28260863 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride alone
Number of subjects: 24
Study 28260863 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride in combination with rosuvastatin
Number of subjects: 24
Study 28260863 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin alone
Number of subjects: 24
Study 28260863 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin in combination with glimepiride
Number of subjects: 24
Study 25642461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-filled resin-modified glass ionomer (Ketac Nano; KN)
Number of subjects: 60
Study 25642461 — intervention group
Group type: COMPARATOR
Intervention: Conventional resin-modified glass ionomer (Vitremer; VR)
Number of subjects: 60
Study 25642461 — intervention group
Group type: EXPERIMENTAL
Intervention: Both materials (KN and VR)
Number of subjects: 60
Study 23676106 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture (once a day for 6 months)
Number of subjects: 86
Study 23676106 — intervention group
Group type: COMPARATOR
Intervention: Oral metformin (250 mg three times daily in the first week, followed by 500 mg three times daily thereafter)
Number of subjects: 86
Study 20972351 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg) for 6 months in patients with high baseline LDL-C (≥ 100 mg/dL)
Number of subjects: 180
Study 20972351 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg) for 6 months in patients with low baseline LDL-C (< 100 mg/dL)
Number of subjects: 180
Study 20361714 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of cardamom powder administered in two divided doses for 12 weeks
Number of subjects: 20
Study 17234798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia (IH) followed by continuous hypoxia (CH) for 12 days
Number of subjects: 14
Study 17234798 — intervention group
Group type: COMPARATOR
Intervention: Continuous hypoxia (CH) for 12 days without prior intermittent hypoxia (IH)
Number of subjects: 14
Study 14746950 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 180
Study 14746950 — intervention group
Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 180
Study 11282259 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5mg/kg)
Number of subjects: 15
Study 11282259 — intervention group
Group type: COMPARATOR
Intervention: Memantine (0.16 mg/kg)
Number of subjects: 15
Study 11282259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9091325 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 5145
Study 9091325 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic procedure
Number of subjects: 5145
Study 9091325 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial or total salpingectomy
Number of subjects: 5145
Study 9091325 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose methotrexate
Number of subjects: 5145
Study 9091325 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 5145
Study 9091325 — intervention group
Group type: COMPARATOR
Intervention: Conservative surgery
Number of subjects: 5145
Study 7699618 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment strategies
Number of subjects: 97
Study 3129807 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP 0.4 microgram kg‐1 intravenous (i.v.)
Number of subjects: 6
Study 3129807 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP 0.4 microgram kg‐1 subcutaneous (s.c.)
Number of subjects: 6
Study 28993287 — intervention group
Group type: EXPERIMENTAL
Intervention: Certified diabetes educators (CDEs) implementing standardized protocols to intensify treatment
Number of subjects: 240
Study 28993287 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study 26957281 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg/day)
Number of subjects: 125
Study 26957281 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study 26434249 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of APE (71.64-72.36 mg/day)
Number of subjects: 60
Study 26434249 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of APE (119.64-120.36 mg/day)
Number of subjects: 60
Study 26434249 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil (300 mg/day)
Number of subjects: 60
Study 23552120 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg thrice weekly after dialysis for 4 months)
Number of subjects: 14
Study 23552120 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 months prior to spironolactone)
Number of subjects: 14
Study 24843534 — intervention group
Group type: EXPERIMENTAL
Intervention: olmesartan (20mg/day)/azelnidipine (16mg/day)
Number of subjects: 39
Study 24843534 — intervention group
Group type: COMPARATOR
Intervention: olmesartan (20mg/day)/trichlormethiazide (1mg/day)
Number of subjects: 39
Study 18218298 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (dexibuprofen 400 mg by Emcure Pharmaceuticals)
Number of subjects: 24
Study 18218298 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (dexibuprofen 400 mg by Genus Pharmaceuticals)
Number of subjects: 24
Study 16272449 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg intravenous hydrocortisone every 6 h
Number of subjects: 93
Study 16272449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 12808270 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg daily)
Number of subjects: 132
Study 12808270 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan plus probucol (500 mg daily)
Number of subjects: 132
Study 12808270 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study 10232493 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (5 mg)
Number of subjects: 23
Study 10232493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 8561323 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 60
Study 8561323 — intervention group
Group type: COMPARATOR
Intervention: Tracheal Tube (TT)
Number of subjects: 60
Study 1681355 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol plus isosorbide mononitrate
Number of subjects: 18
Study 1681355 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol plus nifedipine
Number of subjects: 18
Study 1681355 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (atenolol plus isosorbide mononitrate and nifedipine)
Number of subjects: 18
Study 1681355 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 18
Study 1681355 — intervention group
Group type: COMPARATOR
Intervention: Atenolol alone
Number of subjects: 18
Study 6307330 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (0.5 mg i.v.)
Number of subjects: 7
Study 6307330 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (1 mg i.v.)
Number of subjects: 7
Study 6307330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 28644680 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory factor analysis with the exploratory group
Number of subjects: 488
Study 28644680 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory factor analysis
Number of subjects: 488
Study 28644680 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group
Number of subjects: 488
Study 28644680 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORS‐G scales
Number of subjects: 488
Study 28644680 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORS‐G
Number of subjects: 488
Study 27002748 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week peer-led exercise and education intervention
Number of subjects: 0
Study 27002748 — intervention group
Group type: COMPARATOR
Intervention: Educational workbooks
Number of subjects: 0
Study 24989831 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention with diet counselling and physical activities
Number of subjects: 360